Dopaminergic Modulation of Flexible Cognitive Control in Humans

Dopamine Handbook

Volumn , Issue , 2010, Pages

  Cools, Roshan ^a   D'Esposito, Mark ^b  

^a RADBOUD UNIVERSITY NIJMEGEN   (Netherlands)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cognitive control; Dopamine; Prefrontal cortex; Striatum

Indexed keywords

EID: 84918862992     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1093/acprof:oso/9780195373035.003.0017     Document Type: Chapter

References (94)

1. Fuster J. The Prefrontal Cortex. New York: Raven Press; 1989.
2. Miller E, Cohen J. An integrative theory of prefrontal cortex function. Annu Rev Neurosci. 2001;24:167-202.
3. Chao L, Knight R. Human prefrontal lesions increase distractibility to irrelevant sensory inputs. Neuroreport. 1995;6(12):1605-1610.
4. Miller B, D'Esposito M. Searching for "the top" in top-down control. Neuron. 2005;48(4):535-538.
5. Robbins TW. Chemical neuromodulation of frontal-executive functions in humans and other animals. Exp Brain Res. 2000;133(1):130-138.
6. Arnsten AFT. Catecholamine modulation of prefrontal cortical cognitive function. Trends Cogn Sci. 1998;2(11):436-446.
7. Frank M, Loughry B, O'Reilly R. Interactions between frontal cortex and basal ganglia in working memory: a computational model. Cogn Affect Behav Neurosci. 2001;1(2):137-160.
8. Bilder R, Volavka K, Lachman H, Grace A. The catechol-Omethyltransferase polymorphism: relations to the tonic-phasic dopamine hypothesis and neuropsychiatric phenotypes. Neuropsychopharmacology. 2004;29(11):1943-1961.
9. Cools R, Robbins TW. Chemistry of the adaptive mind. Philos Transact A Math Phys Eng Sci. 2004;362(1825):2871-2888.
10. Cools R. Dopaminergic modulation of cognitive function-implications for L-DOPA treatment in Parkinson's disease. Neurosci Biobehav Rev. 2006;30(1):1-23.
11. Kramer A, Cepeda N, Cepeda M. Methylphenidate effects on taskswitching performance in attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2001;40(11):1277-1284.
12. Wilder J. Paradoxic reactions to treatment. NY State J Med. 1957;57:3348-3352.
13. Dews P. Rate-dependency hypothesis. Science. 1977;198:1182-1183.
14. Dews PB. Studies on behavior. IV. Stimulant actions of methamphetamine. J Pharmacol Exp Ther. 1958;122(137-147).
15. Kimberg DY, D'Esposito M, Farah MJ. Effects of bromocriptine on human subjects depend on working memory capacity. Neuroreport. 1997;8:3581-3585.
16. Granon S, Passetti F, Thomas KL, Dalley JW, Everitt BJ, Robbins T. Enhanced and impaired attentional performance after infusion of D1 dopaminergic receptor agents into rat prefrontal cortex. J Neurosci. 2000;20(3):1208-1215.
17. Mehta M, Owen AM, Sahakian BJ, Mavaddat N, Pickard JD, Robbins TW. Methylphenidate enhances working memory by modulating discrete frontal and parietal lobe regions in the human brain. J Neurosci. 2000(RC 65):1-6.
18. Mattay VS, Callicot JH, Bertolino A, et al. Effects of dextroamphetamine on cognitive performance and cortical activation. Neuroimage. 2000;12(3):268-275.
19. Baddeley AD. Working Memory. Oxford: Clarendon Press; 1986.
20. Brozoski TJ, Brown R, Rosvold HE, Goldman PS. Cognitive deficit caused by regional depletion of dopamine in the prefrontal cortex of rhesus monkeys. Science. 1979;205:929-931.
21. Sawaguchi T, Goldman-Rakic PS. D1 dopamine receptors in prefrontal cortex: involvement in working memory. Science. 1991;251:947-950.
22. Sawaguchi T, Matsumura M, Kubota K. Effects of dopamine antagonists on neuronal activity related to a delated response task in monkey prefrontal cortex. J Neurophysiol. 1990;63(6):1401-1412.
23. Sawaguchi T, Matsumura M, Kubota K. Catecholaminergic effects on neuronal activity related to a delayed response task in monkey prefrontal cortex. J Neurophysiol. 1990;63(6):1385-1399.
24. Luciana L, Collins PF, Depue RA. Opposing roles for dopamine and serotonin in the modulation of human spatial working memory functions. Cereb Cortex. 1998;8:218-226.
25. Luciana M, Collins P. Dopaminergic modulation of working memory for spatial but not object cues in normal volunteers. J Cogn Neurosci. 1997;9:330-347.
26. Luciana M, Depue RA, Arbisi P, Leon A. Facilitation of working memory in humans by a D2 dopamine receptor agonist. J Cogn Neurosci. 1992;4(1):58-68.
27. Daneman M, Carpenter P. Individual differences in working memory and reading. J Verbal Learn Verbal Behav. 1980;19:450-466.
28. Salthouse T, Babcock R. Decomposing adult age differences in working memory. Dev Psychol. 1991;27(762-766).
29. Kimberg D, D'Esposito M. Cognitive effects of the dopamine receptor agonist pergolide. Neuropsychologia. 2003;41(8):1020-1007.
30. Cools R, Sheridan M, Jacobs E, D'Esposito M. Impulsive personality predicts dopamine-dependent changes in frontostriatal activity during component processes of working memory. J Neurosci. 2007;27(20):5506-5514.
31. Gibbs SE, D'Esposito M. Individual capacity differences predict working memory performance and prefrontal activity following dopamine receptor stimulation. Cogn Affect Behav Neurosci. 2005;5(2):212-221.
32. Gibbs SE, D'Esposito M. A functional magnetic resonance imaging study of the effects of pergolide, a dopamine receptor agonist, on component processes of working memory. Neuroscience. 2006;139(1):359-371.
33. Frank MJ, O'Reilly RC. A mechanistic account of striatal dopamine function in human cognition: psychopharmacological studies with cabergoline and haloperidol. Behav Neurosci. 2006;120(3):497-517.
34. Mehta M, Calloway P, Sahakian B. Amelioration of specific working memory deficits by methylphenidate in a case of adult attention deficit/ hyperactivity disorder. J Psychopharmacol. 2000;14(3):299-302.
35. Phillips A, Ahn S, Floresco S. Magnitude of dopamine release in medial prefrontal cortex predicts accuracy of memory on a delayed response task. J Neurosci. 2004;14(2):547-553.
36. Williams GV, Goldman-Rakic PS. Modulation of memory fields by dopamine D1 receptors in prefrontal cortex. Nature. 1995;376:572-575.
37. Zahrt J, Taylor JR, Mathew RG, Arnsten AFT. Supranormal stimulation of D1 dopamine receptors in the rodent prefrontal cortex impairs spatial working memory performance. J Neurosci. 1997;17(21):8528-8535.
38. Vijayraghavan S, Wang M, Birnbaum S, Williams G, Arnsten A. Inverted-U dopamine D1 receptor actions on prefrontal neurons engaged in working memory. Nat Neurosci. 2007;10(3):176-184.
39. Mattay V, Goldberg T, Fera F, et al. Catechol-O-methyltransferase Val158 -met genotype and individual variation in the brain response to amphetamine. Proc Natl Acad Sci USA. 2003;100(10):6186-6191.
40. Floresco S, Phillips A. Delay-dependent modulation of memory retrieval by infusion of a dopamine D1 agonist into the rat medial prefrontal cortex. Behav Neurosci. 2001;115(4):934-939.
41. Cools R, Frank M, Gibbs S, Miyakawa A, Jagust W, D'Esposito M. Striatal dopamine synthesis capacity predicts dopaminergic drug effects on flexible outcome learning. J Neurosci. 2009;29:1538-1543.
42. Collins P, Roberts AC, Dias R, Everitt BJ, Robbins TW. Perseveration and strategy in a novel spatial self-ordered sequencing task for nonhuman primates: effects of excitotoxic lesions and dopamine depletions of the prefrontal cortex. J Cogn Neurosci. 1998;10(3):332-354.
43. Roberts AC, De Salvia MA, Wilkinson LS, et al. 6-Hydroxydopamine lesions of the prefrontal cortex in monkeys enhance performance on an analog of the Wisconsin Card Sort Test: possible interactions with subcortical dopamine. J Neurosci. 1994;14(5):2531-2544.
44. Crofts HS, Dalley JW, Van Denderen JCM, Everitt BJ, Robbins TW, Roberts AC. Differential effects of 6-OHDA lesions of the frontal cortex and caudate nucleus on the ability to acquire an attentional set. Cereb Cortex. 2001;11(11):1015-1026.
45. Mehta MA, Swainson R, Ogilvie AD, Sahakian BJ, Robbins TW. Improved short-term spatial memory but impaired reversal learning following the dopamine D2 agonist bromocriptine in human volunteers. Psychopharmacology. 2001;159:10-20.
46. Mehta M, Manes F, Magnolfi G, Sahakian B, Robbins T. Impaired setshifting and dissociable effects on tests of spatial working memory following the dopamine D2 receptor antagonist sulpiride in human volunteers. Psychopharmacology. 2004; 176(3-4):331-42.
47. Nolan K, Bilder R, Lachman H, Volavka K. Catechol-O-methyltransferase Val158Met polymorphism in schizophrenia: differential effects of Val and Met alleles on cognitive stability and flexibility. Am J Psychiaty. 2004;161:359-361.
48. Lotta T, Vidgren J, Tilgmann C, et al. Kinetics of human soluble and membrane-bound catechol-O-methyltransferase: a revised mechanism and description of the thermolabile variant of the enzyme. Biochemistry. 1995;34:4202-4210.
49. Chen J, Lipska B, Halim N, et al. Functional analysis of genetic variation in catechol-O-methyltransferase (COMT): effects on mRNA, protein, and enzyme activity in postmortem human brain. Am J Genet. 2004;75:807-821.
50. Druzin M, Kurzina N, Malinina E, Kozlov A. The effects of local application of D2 selective dopaminergic drugs into the medial (p.259) prefrontal cortex of rats in a delayed spatial choice task. Behav Brain Res. 2000;109(1):99-111.
51. Durstewitz D, Seamans J. The dual-state theory of prefrontal cortex dopamine function with relevance to catechol-O-methyltransferase genotypes and schizophrenia. Biol Psychiatry. 2008;64(9):739-749.
52. Seamans JK, Yang CR. The principal features and mechanisms of dopamine modulation in the prefrontal cortex. Prog Neurobiol. 2004;74(1):1-58.
53. Frank MJ, Seeberger LC, O'Reilly RC. By carrot or by stick: cognitive reinforcement learning in parkinsonism. Science. 2004;306(5703):1940-1943.
54. Cools R, Altamirano L, D'Esposito M. Reversal learning in Parkinson's disease depends on medication status and outcome valence. Neuropsychologia. 2006;44(10):1663-1673.
55. Durstewitz D, Seamans J, Sejnowski T. Dopamine-mediated stabilization of delay-period activity in a network model of prefrontal cortex. J Neurophysiol. 2000;83:1733-1750.
56. Frank MJ. Dynamic dopamine modulation in the basal ganglia: a neurocomputational account of cognitive deficits in medicated and nonmedicated Parkinsonism. J Cogn Neurosci. 2005;17(1):51-72.
57. Zhang Y, Bertolino A, Fazio L, et al. Polymorphisms in human dopamine D2 receptor gene affect gene expression, splicing, and neuronal activity during working memory. Proc Natl Acad Sci USA. 2007;104(51):20552-20557.
58. Meyer-Lindenberg A, Straub RE, Lipska BK, et al. Genetic evidence implicating DARPP-32 in human frontostriatal structure, function, and cognition. J Clin Invest. 2007;117(3):672-682.
59. Gruber AJ, Dayan P, Gutkin BS, Solla SA. Dopamine modulation in the basal ganglia locks the gate to working memory. J Comput Neurosci. 2006;20(2):153-166.
60. McNab F, Klingberg T. Prefrontal cortex and basal ganglia control access to working memory. Nat Neurosci. 2008;11(1):103-107.
61. Leber A, Turk-Browne N, Chun M. Neural predictors of moment-tomoment fluctuations in cognitive flexibility. Proc Natl Acad Sci USA. 2008;105(36):13592-13597.
62. Cools AR. Role of the neostriatal dopaminergic activity in sequencing and selecting behavioural strategies: facilitation of processes involved in selecting the best strategy in a stressful situation. Behav Brain Res. 1980;1:361-378.
63. Lyon M, Robbins TW. The action of central nervous system stimulant drugs: a general theory concerning amphetamine effects. In: Essman W, ed. Current Developments in Psychopharmacology, Vol 2. New York: Spectrum; 1975:79-163.
64. Pycock CJ, Kerwin RW, Carter CJ. Effect of lesion of cortical dopamine terminals on subcortical dopamine receptors in rats. Nature. 1980;286:74-77.
65. Meyer-Lindenberg A, Kohn PD, Kolachana B, et al. Midbrain dopamine and prefrontal function in humans: interaction and modulation by COMT genotype. Nat Neurosci. 2005;8(5):594-596.
66. Akil M, Kolachana BS, Rothmond DA, Hyde TM, Weinberger DR, Kleinman JE. Catechol-O-methyltransferase genotype and dopamine regulation in the human brain. J Neurosci. 15 2003;23(6):2008-2013.
67. Bertolino A, Blasi G, Latorre V, et al. Additive effects of genetic variation in dopamine regulating genes on working memory cortical activity in human brain. J Neurocsci. 2006;26(15):3918-3922.
68. Caldu X, Vendrell P, Bartres-Faz D, et al. Impact of the COMT Val108/158 Met and DAT genotypes on prefrontal function in healthy subjects. Neuroimage. 2007;37(4):1437-1444.
69. Dodds CM, Muller U, Clark L, van Loon A, Cools R, Robbins TW. Methylphenidate has differential effects on blood oxygenation leveldependent signal related to cognitive subprocesses of reversal learning. J Neurosci. 2008;28(23):5976-5982.
70. Cools R, Clark L, Owen AM, Robbins TW. Defining the neural mechanisms of probabilistic reversal learning using event-related functional magnetic resonance imaging. J Neurosci. 2002;22(11):4563-4567.
71. Cools R, Barker RA, Sahakian BJ, Robbins TW. Enhanced or impaired cognitive function in Parkinson's disease as a function of dopaminergic medication and task demands. Cereb Cortex. 2001;11:1136-1143.
72. Cools R, Lewis S, Clark L, Barker R, Robbins TW. L-DOPA disrupts activity in the nucleus accumbens during reversal learning in Parkinson's disease. Neuropsychopharmacology. 2007;32:180-189.
73. Cools R, Gibbs S, Miyakawa A, Jagust W, D'Esposito M. Working memory capacity predicts dopamine synthesis capacity in the human striatum. J Neurosci. 2008;28:1208-1212.
74. Sawamoto N, Piccini P, Hotton G, Pavese N, Thielemans K, Brooks D. Cognitive deficits and striato-frontal dopamine release in Parkinson's disease. Brain 2008;131(5):1294-1302.
75. Agid Y, Ruberg M, Javoy-Agid F, et al. Are dopaminergic neurons selectively vulnerable to Parkinson's disease? Adv Neurol. 1993;60:148-164.
76. Rakshi J, Uema T, Ito K, et al. Frontal, midbrain and striatal dopamergic function in early and advanced Parkinson's disease. A 3D [(18)F]dopa-PET study. Brain. 1999;122(1637-1650).
77. Kaasinen V, Nurmi E, Bruck A, et al. Increased frontal [(18)F]fluorodopa uptake in early Parkinson's disease: sex differences in the prefrontal cortex. Brain. 2001;124:1125-1130.
78. Bowen FP, Kamienny RS, Burns MM, Yahr MD. Parkinsonism: effects of levodopa treatment on concept formation. Neurology. 1975;25:701-704.
79. Lees AJ, Smith E. Cognitive deficits in the early stages of Parkinson's disease. Brain. 1983;106:257-270.
80. Taylor A, Saint-Cyr J. The neuropsychology of Parkinson's disease. Brain Cogn. 1995;28:281-296.
81. Cools AR, Van Den Bercken JHL, Horstink MWI, Van Spaendonck KPM, Berger HJC. Cognitive and motor shifting aptitude disorder in Parkinson's disease. J Neurol Neurosurg Psychiatry. 1984;47:443-453.
82. Downes JJ, Roberts AC, Sahakian BJ, Evenden JL, Morris RG, Robbins TW. Impaired extra-dimensional shift performance in medicated and unmedicated Parkinson's disease: evidence for a specific attentional dysfunction. Neuropsychologia. 1989;27:1329-1343.
83. Owen AM, James M, Leigh JM, et al. Fronto-striatal cognitive deficits at different stages of Parkinson's disease. Brain. 1992;115:1727-1751.
84. Owen AM, Sahakian BJ, Hodges JR, Summers BA, Polkey CE, Robbins TW. Dopamine-dependent frontostriatal planning deficits in early Parkinson's disease. Neuropsychology. 1995;9:126-140.
85. Pollux P, Robertson C. Reduced task-set inertia in Parkinson's disease. J Clin Exp Neuropsychol. 2002;24(8):1046-1056.
86. Pollux P. Advance preparation of set-switches in Parkinson's disease. Neuropsychologia. 2004;42(7):912-919.
87. Rogers RD, Sahakian BJ, Hodges JR, Polkey CE, Kennard C, Robbins TW. Dissociating executive mechanisms of task control following frontal lobe damage and Parkinson's disease. Brain. 1998;121:815-842.
88. Cools R, Barker RA, Sahakian BJ, Robbins TW. Mechanisms of cognitive set flexibility in Parkinson's disease. Brain. 2001;124:2503-2512.
89. Rogers RD, Monsell S. Costs of a predictable switch between simple cognitive tasks. J Exp Psychol. 1995;124:207-231.
90. Hayes AE, Davidson MC, Keele SW. Towards a functional analysis of the basal ganglia. J Cogn Neurosci. 1998;10(2):178-198.
91. Cools R, Barker RA, Sahakian BJ, Robbins TW. L-Dopa medication remediates cognitive inflexibility, but increases impulsivity in patients with Parkinson's disease. Neuropsychologia. 2003;41:1431-1441.
92. Cools R, Miyakawa A, D'Esposito M. Dopaminergic modulation of distractor-resistent working memory in healthy volunteers and Parkinson's disease. Comparison with frontal lobe lesions. Paper presented at The Society for Neuroscience Annual Meeting, 2007; San Diego, CA.
93. Gerlach M, Double K, Arzberger T, Leblhuber F, Tatschner T, Riederer P. Dopamine receptor agonists in current clinical use: comparative dopamine receptor binding profiles defined in the human striatum. J Neural Transm. 2003;110(10):1119-1127.
94. De Keyser J, De Backer J-P, Wilczack N, Herroelen L. Dopamine agonists used in the treatment of Parkinson's disease and their selectivity for the D1, D2, and D3 dopamine receptors in human striatum. Prog Neuropsychopharmacol Biol Psychiatry. 1995;19:1147-1154.